Skip to Main content Skip to Navigation
Journal articles

Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis with Biological Agents: Efficacy monitoring of biological agents in Multiple Sclerosis

Abstract : Multiple sclerosis is a heterogenous disease. Although several EMA-approved disease-modifying treatments including biopharmaceuticals are available, their efficacy is limited, and a certain percentage of patients are always nonresponsive. Drug efficacy monitoring is an important tool to identify these nonresponsive patients early on. Currently, detection of antidrug antibodies and quantification of biological activity are used as methods of efficacy monitoring for interferon beta and natalizumab therapies. For natalizumab and alemtuzumab treatments, drug level quantification could be an essential component of the overall disease management. Thus, utilization and development of strategies to determine treatment response are vital aspects of multiple sclerosis management given the tremendous clinical and economic promise of this tool.
Complete list of metadatas

Cited literature [10 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01755556
Contributor : William Raoul <>
Submitted on : Friday, March 30, 2018 - 4:42:25 PM
Last modification on : Wednesday, December 4, 2019 - 2:38:03 PM

File

2017TDMaccepted.pdf
Files produced by the author(s)

Identifiers

Collections

Citation

Marzia Caldano, William Raoul, Theo Rispens, Antonio Bertolotto. Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis with Biological Agents: Efficacy monitoring of biological agents in Multiple Sclerosis. Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2017, 39 (4), pp.350 - 355. ⟨10.1097/FTD.0000000000000393⟩. ⟨inserm-01755556⟩

Share

Metrics

Record views

137

Files downloads

321